IP Verse

InvaGen Pharmaceuticals, Inc. et al. vs Bayer Pharma AG et al.

The detailed information for PTAB case with proceeding number IPR2022-01515 filed by InvaGen Pharmaceuticals, Inc. et al. against Bayer Pharma AG et al. on Sep 8, 2022. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Case Details

Proceeding Number: IPR2022-01515
Filing Date: Sep 8, 2022
Petitioner: InvaGen Pharmaceuticals, Inc. et al.
Respondent: Bayer Pharma AG et al.
Status: Final Written Decision - Appealed
Respondent Application Number: 16264032
Respondent Tech Center: 1600
Respondent Patent Number: 10828310
Institution Decision Date: Oct 19, 2022
Termination Date: Jul 28, 2023

Proceeding Documents

The table below shows documents filed in the case, listing each document name, filing date, document type, and filing party. Tracking these filings indicates the activity of the parties involved in the case, and the types of documents filed can provide insights into the legal strategies being employed.

Show Exhibit Documents

Document Name	Filing Date	Category	Filing Party
Alert me when new update on this case
Determining All Challenged Claims Unpatentable 35 U.S.C. § 318(a)	Jul 28, 2023	PAPER	BOARD
ORDER Granting Petitioners Motion for Pro Hac Vice Admission of Teresa M. Summers 37 C.F.R. sec 42.10	Nov 8, 2022	PAPER	BOARD
Institution Decision: Joined	Oct 19, 2022	PAPER	BOARD
Petitioner's Exhibit List	Oct 6, 2022	PAPER	PETITIONER
Transcript of Board Telephone Conference on September 21, 2022	Oct 6, 2022	EXHIBIT	PETITIONER
Joint Notice of Stipulation Concerning Joinder	Oct 6, 2022	PAPER	PATENT OWNER
Petitioner's Motion for Pro Hac Vice Admission of Teresa M. Summers, Esq.	Sep 29, 2022	PAPER	PETITIONER
Declaration of Teresa M. Summers, Esq.	Sep 29, 2022	EXHIBIT	PETITIONER
NOTICE OF FILING DATE ACCORDED TO PETITION AND TIME FOR FILING PATENT OWNER PRELIMINARY RESPONSE	Sep 27, 2022	PAPER	BOARD
Patent Owner Power of Attorney	Sep 21, 2022	PAPER	PATENT OWNER
Patent Owner Mandatory Notices	Sep 21, 2022	PAPER	PATENT OWNER
U.S. Patent No. 10,828,310	Sep 8, 2022	EXHIBIT	PETITIONER
Expert Declaration of Dr. Randall M. Zusman, M.D.	Sep 8, 2022	EXHIBIT	PETITIONER
Curriculum Vitae of Dr. Randall M. Zusman, M.D.	Sep 8, 2022	EXHIBIT	PETITIONER
File History of U.S. Patent Application No. 16/264,032 (Part 1)	Sep 8, 2022	EXHIBIT	PETITIONER
File History of U.S. Patent Application No. 16/264,032 (Part 2)	Sep 8, 2022	EXHIBIT	PETITIONER
File History of U.S. Patent Application No. 16/264,032 (Part 3)	Sep 8, 2022	EXHIBIT	PETITIONER
European Medicines Agency, Assessment Report, Xarelto, EMA/CHMP/794349/2012, 2013	Sep 8, 2022	EXHIBIT	PETITIONER
Foley, T. R., et al., Antithrombotic therapy in peripheral artery disease, VASCULAR MED., 21(2), 2016, 156-69	Sep 8, 2022	EXHIBIT	PETITIONER
Plosker, G. L., Rivaroxaban: A Review of Its Use in Acute Coronary Syndromes, DRUGS, 74, 2014, 451-64	Sep 8, 2022	EXHIBIT	PETITIONER
Amsterdam, E. A., et al., 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes, J. AM. COL. CARDIOL., 64(24), 2014, e139-228	Sep 8, 2022	EXHIBIT	PETITIONER
Kubitza, D., et al., Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban��an Oral Direct Factor Xa Inhibitor��Are Not Affected by Aspirin, J. CLIN. PHARMACOL., 46 (2006), 981-90	Sep 8, 2022	EXHIBIT	PETITIONER
U.S. Patent Publication No. 2004/0242660, Substituted Oxazolidinones for Combinatorial Therapy, published Dec. 2, 2004 to Straub et al.	Sep 8, 2022	EXHIBIT	PETITIONER
Barstow, C., et al., Acute Coronary Syndrome: Diagnostic Evaluation, AM. FAM. PHYS., 95(3), 2017, 170-77	Sep 8, 2022	EXHIBIT	PETITIONER
Braunwald, E. & Mann, D., Braunwald��s Heart Disease: A Textbook of Cardiovascular Medicine (10th ed.) 2015, Elsevier Saunders.	Sep 8, 2022	EXHIBIT	PETITIONER
Dressman, J. B., et al., Biowaiver Monograph for Immediate- Release Solid Oral Dosage Forms: Acetylsalicylic Acid, J. PHARM. SCI., 101(8), 2012, 2653-67	Sep 8, 2022	EXHIBIT	PETITIONER
Mega, J. L., et al., Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial, LANCET, 374, 2009, 29-38	Sep 8, 2022	EXHIBIT	PETITIONER
Mega, J. L., et al., Rivaroxaban in Patients with a Recent Acute Coronary Syndrome, N. ENG. J. MED., 366(1), 2012, 9-19	Sep 8, 2022	EXHIBIT	PETITIONER
U.S. FDA Approves XARELTO�� (rivaroxaban) to Reduce the Risk of Major Cardiovascular Events in Patients with Chronic Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD)	Sep 8, 2022	EXHIBIT	PETITIONER
Deichmann, R. E., et al., Considerations for Stopping a Clinical Trial Early, OCHSNER J. 16(3), 2016, 197-98	Sep 8, 2022	EXHIBIT	PETITIONER
Siegal, D. M., et al., Adexanet Alfa for the Reversal of Factor Xa Inhibitor Activity, N. ENG. J. MED., 373(25), 2015, 2413-24	Sep 8, 2022	EXHIBIT	PETITIONER
European Medicines Agency, Xarelto	Sep 8, 2022	EXHIBIT	PETITIONER
Sivolella, S., et al., Managing dentoalveolar surgical procedures in patients taking new oral anticoagulants, ODONTOL., 103(3), 2015, 258-63	Sep 8, 2022	EXHIBIT	PETITIONER
Curriculum Vitae of Dr. Mark J. Eisenberg, M.D.	Sep 8, 2022	EXHIBIT	PETITIONER
Petitioner's Power of Attorney	Sep 8, 2022	PAPER	PETITIONER
Petition	Sep 8, 2022	PAPER	PETITIONER
Expert Declaration of Dr. Mark J. Eisenberg, M.D.	Sep 8, 2022	EXHIBIT	PETITIONER
Motion for Joinder	Sep 8, 2022	PAPER	PETITIONER